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Abstract
Purpose To identify patient characteristics that influence ta-
crolimus individual dose requirement in kidney transplant
recipients.
Methods Data on forty-four 12-h pharmacokinetic profiles
from 29 patients and trough concentrations in 44 patients
measured during the first 70 days after transplantation
(1,546 tacrolimus whole blood concentrations) were analyzed.
Population pharmacokinetic modeling was performed using
NONMEM 7.2®.
Results Standardization of tacrolimus whole blood concentra-
tions to a hematocrit value of 45 % improved the model fit
significantly (p<0.001). Fat-free mass was the best body size
metric to predict tacrolimus clearance and volume of distribution.
Bioavailability was 49 % lower in expressers of cytochrome
P450 3A5 (CYP3A5) than in CYP3A5 nonexpressers. Younger
females (<40 years) showed a 35 % lower bioavailability than
younger males. Bioavailability increased with age for both males
and females towards a common value at age >55 years that was
47% higher than themale value at age <40 years. Bioavailability
was highest immediately after transplantation, decreasing steeply
thereafter to reach its nadir at day 5, following which it increased
during the next 55 days towards an asymptotic value that was
28 % higher than that on day 5.
Conclusions Hematocrit predicts variability in tacrolimus whole
blood concentrations but is not expected to influence unbound
(therapeutically active) concentrations. Fat-free mass, CYP3A5
genotype, sex, age and time after transplant influence the tacro-
limus individual dose requirement. Because hematocrit is highly
variable in kidney transplant patients and increases substantially
after kidney transplantation, hematocrit is a key factor in the
interpretation of tacrolimus whole blood concentrations.
Keywords Tacrolimus . Hematocrit . Fat-freemass .
Population pharmacokinetics . Target concentration
intervention . Kidney transplantation
Introduction
Tacrolimus is an immunosuppressive drug widely used after
kidney transplantation. Applying a target concentration strategy
is recommended to ensure adequate immunosuppression
[1]. The initial dose of tacrolimus is typically calculated in
proportion to total bodyweight, with subsequent doses adjusted
on the basis of whole blood trough concentration measure-
ments. The target concentration for initial and subsequent dos-
ing varies from center to center with no detectable relationship
between achieved whole blood concentrations and the risk of
acute rejection [2]. Predicting the individual dose requirement
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to achieve and maintain the desired target whole blood concen-
tration of tacrolimus is challenging due to considerable vari-
ability in apparent whole blood clearance (CL/F) between
patients [coefficient of variance (CV) 30–42 %] as well as
between dosing occasions within patients (CV 40–71 %) [3].
In addition, dose-normalized whole blood concentrations of
tacrolimus tend to increase during the first months after kidney
transplantation, which has led to the suggestion of time-
dependent pharmacokinetics [4, 5]. Both under- and overdosing
frequently occur during this period, and several dose adjust-
ments are typically performed [6].
Tacrolimus distributes into and binds to erythrocytes, show-
ing a blood-to-plasma ratio of approximately 50 with a hemat-
ocrit of 45 % [7], and the unbound fraction in the blood is <1%
[8]. The drug is routinely measured as total concentrations in
whole blood, although the unbound concentration is expected
to mediate the pharmacological effect. Hebert et al. [9] have
recently reviewed the pharmacological principles underlying
the interpretation of whole blood concentrations and pointed
out the potential dangers of adjusting tacrolimus doses based on
whole blood concentration alone. Since tacrolimus is a low-
extraction-ratio drug [10], whole blood concentrations are
expected to increase in proportion to erythrocyte binding (pro-
portional to hematocrit), while the unbound, therapeutically
active concentration remains unchanged. At the time of kidney
transplant, hematocrit is generally low, and it usually increases
during the first months after transplantation as the recipients
recover from kidney failure and erythrocyte production normal-
izes [11]. Because changes in hematocrit are expected to change
the concentration of bound tacrolimus without modifying the
unbound concentration [9], this trend should not be interpreted
as the need for dose adjustment. It is currently unclear how
much of the apparent time-dependent pharmacokinetics of
tacrolimus during the first post-transplant months are explained
by changes in hematocrit.
In this study, a population pharmacokinetic model for tacro-
limus was developed using data from adult kidney transplant
recipients. The purpose was to identify patient characteristics that
influence tacrolimus individual dose requirement. Measured
whole blood concentrations of tacrolimus were standardized to
a normal hematocrit value (45%). This led to the development of
a pharmacokinetic model that can be used to individualize tacro-
limus dosing to achieve a target concentration that better reflects
the unbound pharmacologically active drug.
Materials and methods
Patients and data
Data on a total of 1,546 tacrolimus whole blood concentrations
were obtained from 69 adult patients who underwent kidney
transplantation at Oslo University Hospital, Rikshospitalet and
who received tacrolimus as part of their immunosuppressive
therapy. Patients who received multiple organs or who received
drugs that were known to pharmacokinetically interact with
tacrolimus were excluded. However, if such drugs were used
by >5 % of the patients, the patients were allowed in the
analysis, and the drug was analyzed as a covariate. The patients
contributed data to an Intensive Group or a TDM (therapeutic
drug monitoring) Group. Four patients contributed data to both
groups. The Intensive Group consisted of 12-h concentration–
time profiles from 29 patients in a stable phase after transplan-
tation (range 26 days–18 years). The data were collected on a
total of 44 dosing occasions as described in three previously
published studies [12–14]. The TDM Group consisted of rou-
tine trough concentrations (C0) measured in 44 patients during
the first 70 days following kidney transplantation. Dosing at
12-h intervals and full compliance were presumed unless
missed doses were recorded in the patient chart. Patients were
told to be fasting at the time of drug intake.
The following data were collected for covariate analysis:
cytochrome P450 3A5 (CYP3A5) genotype, hematocrit, sex,
age, total body weight, height, serum albumin, serum creati-
nine, C-reactive protein, aspartate aminotransferase, alanine
aminotransferase, total serum bilirubin, alkaline phosphatase,
acute rejection episodes, oral prednisolone dose, intravenous
methylprednisolone dose, and use of other potentially interac-
tive drugs. Covariates with time-dependent values were up-
dated for each recorded tacrolimus measurement. Covariates
missing on the day of transplantation were imputed by carry-
ing back the first known value. Covariates missing at any later
time point were imputed by carrying forward the last known
value. However, if more than two hematocrit values were
missing in sequence and the hemoglobin level was known,
hematocrit values were derived by linear regression between
all known hematocrit and hemoglobin values within the pa-
tient. A summary of the study designs is listed in Table 1.
The study was approved by the Regional Committee for
Medical Research Ethics and by the Norwegian Medicines
Agency. All patients gave written informed consent.
Immunosuppressive therapy
All patients received oral tacrolimus (Prograf® capsules;
Astellas Pharma US Inc., Northbrook, IL). According to the
center transplant protocol, initial dosage for the TDM Group
was 0.04 mg/kg total body weight (0.05 mg/kg for high-risk
patients) twice daily, adjusted to the nearest 0.5 mg dose. The
dosage was subsequently adapted by measuring whole blood
trough concentrations to maintain concentrations within the
range of 3–7 μg/L in standard risk patients or 8–12 μg/L in
high-risk patients. High-risk patients were defined by panel
reactive antibody of >20 % and/or presence of donor-specific
antibodies. Trough concentrations of tacrolimus were initially
measured three to four times per week. Depending on clinical
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status and graft function, this frequency decreased in parallel
with increasing time since transplantation.
In addition to tacrolimus, the immunosuppressive regimen
for the TDM Group consisted of 0.75 g mycophenolate
mofetil twice daily (without target concentration intervention),
induction therapy with 20 mg of basiliximab on the day of
transplant (day 1) and on day 5, an intravenous bolus of
250 mg methylprednisolone on day 1 and oral prednisolone
once daily according to the following tapering regimen: 20mg
on days 2–15, 15 mg on days 16–29, 10 mg on days 30–61,
7.5 mg on days 62–180 and 5 mg from day 181 onwards.
High-risk patients received induction therapy with 500 mg/kg
intravenous human immune globulins daily on days 1–6 and
375mg/m2 rituximab on day 1, intravenous boluses of 500mg
and 80 mg methylprednisolone on day 1 and 2, respectively,
and oral prednisolone at a total dose of 80 mg on day 3,
followed by tapering during days 4–7 to 30 mg daily, contin-
ued with once-daily doses of 20 mg on days 8–29, 15 mg on
days 30–61, 10 mg from day 62 and in selected patients
tapered to 5 mg from day 181 onwards. For the Intensive
Group, prednisolone dose was the only recorded concomitant
immunosuppressive drug on which information was provided
(range 0–25 mg daily).
Analytical assays
Table 1 shows the analytical assays used to measure tacrolimus
concentrations in each sub-study. Chemiluminescent micropar-
ticle immunoassay (CMIA) is currently used as a standard
analytical method at our center. Of the concentrations available
for analysis, 80 % were determined by CMIA, 9 % by
microparticle enzyme immunoassay (MEIA) and 11%by liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Ta-
crolimus concentrations determined by CMIA and MEIA cor-
relate well at concentrations of >5 μg/L [15]. As only 1% of the
concentrations in the present analysis determined by MEIA
were <5 μg/L, no conversion was performed between immu-
noassay measurements. On the contrary, tacrolimus concen-
trations determined by immunoassay tend to be higher than
those determined by mass spectrometry, mainly due to cross-
reactivity with tacrolimus metabolites [1]. In order to use
tacrolimus concentrations determined by LC-MS/MS in the
present analysis, we converted LC-MS/MS measurements
into CMIA-equivalent measurements by the means of a con-
version equation (Eq. 1) derived from linear regression be-
tween 43 tacrolimus whole blood concentrations determined
by both LC-MS/MS (range 2.7–13.0 μg/L) and CMIA (range
3.6–14.4 μg/L) (R2=0.94). The regression analysis was avail-
able from routine procedures performed at our laboratory
during transition between analytical assays.
CM ¼ LC−0:19ð Þ
0:80
ð1Þ
In Eq. 1, CM is the CMIA tacrolimus concentration in
micrograms per liter and LC is the LC-MS/MS tacrolimus
concentration in micrograms per liter.
CYP3A5 genotyping
DNAwas extracted from EDTA anti-coagulated whole blood
using the MagNA Pure instrument (Roche Applied Science,
Table 1 Characteristics of tacrolimus pharmacokinetic studies







Assay CV (%) Sampling times
1. [12] 134 5b MEIAc 3.0 13 at 5 μg/L 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10
and 12 h after administration7 at 23 μg/L
2. [13] 164 7b LC-MS/MSd 1.1 ≤5.2 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10 and
12 h after administration
3. [14] 216 19b CMIAe 1.0 <6 at 2.3 μg/L 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 23
and 24 h after administration<9 at 7.0 μg/L
4. NPP 1,032 44 CMIAe 1.0 <6 at 2.3 μg/L Predose (trough concentrations)
<9 at 7.0 μg/L
CMIA, Chemiluminescent microparticle immunoassay; CV, between-series coefficient of variation; LC-MS/MS, liquid chromatography/tandem mass
spectrometry; LLOQ, lower limit of quantification; MEIA, microparticle enzyme immunoassay; NPP, not previously published data
a Six patients contributed data to more than one study. These were identified and their data were associated with the same ID in the data set, with an
increase in the number of occasions. The total number of individuals was 69
bNumber of patients is different from number in original study due to exclusion criteria of the present study
cAnalyzed on the IMx® instrument (Abbott Laboratories, Abbott Park, IL)
d Converted to corresponding immunoassay concentrations: CM=(LC−0.19)/0.80; see main text for details
e Analyzed on the Architect® instrument (Abbott Laboratories)
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Penzberg, Germany). CYP3A5 genotyping (rs776746;
NG_007938.1 :g .12083G >A, A=CYP3A5*1 and
G=CYP3A5*3 ) was performed by real-time PCR and melt
curve analysis with hybridization probes on the LightCycler®
480 instrument (Roche Applied Science) or by a previously
reported PCR-restriction fragment length polymorphism as-
say [16]. Primers for the melt curve assay were designed using
LightCycler Probe Design software version 2 (Roche Applied
Science), and hybridization probe sequences were derived
from Cheung et al. [17].
Population pharmacokinetic modeling
Structural model
Models with one or two compartments, zero or first order
absorption and with or without an absorption lag time were
investigated. Pharmacokinetic parameters were estimated in
terms of clearance (CL), intercompartmental clearance (Q)
and volumes of distribution (V1, V2). The population value
of bioavailability (F) was defined as 1, and subgroup values
and individual values of F were estimated relative to the
population value. Because only data following oral adminis-
tration were available, apparent disposition parameter esti-
mates were obtained (e.g. CL/F, V1/F). Random effects in
the pharmacokinetic parameters were modeled in terms of
between subject variability (BSV) and between occasion var-
iability (BOV). BSVand BOV were initially estimated for all
pharmacokinetic parameters except lag time. Random effects
were modeled exponentially (Eq. 2):
Pik ¼ PGRP  eηiþηk ð2Þ
where Pik is the value of parameter P for the i-th individual at
the k-th occasion, PGRP is the group value of P in the popula-
tion, eηi is the deviation between PGRP and the individual
value Pi and e
ηk is the deviance between the individual value
Pi and the occasion-specific value Pik [18]. For the Intensive
Group, one hospital visit was defined as one occasion. For the
TDMGroup, a new occasion was defined when a dose change
took place. Equation 3 shows the residual error model used
throughout the analysis:
Yij ¼ Concij þ θstudyi  ε1  Concij þ ε2
  eηerri ð3Þ
where Yij and Concij are the model-predicted drug concentra-
tions with and without residual error, respectively, for the i-th
individual at the j-th measurement, θstudyi is a study-specific
fixed effect, ε1 is a residual error term proportional to the
measured concentrations, ε2 is an additive error term and e
ηerri
is the individual random difference in residual error for the i-th
individual [19]. The random variables ηi, ηk, ε1, ε2 and ηerri
were assumed to be normally distributed with means of zero







Tacrolimus total concentrations (Ctot) in whole blood are the
sum of the unbound (Cu), plasma bound (Cp) and erythrocyte
bound (Cb) concentrations. Assuming a single binding site,
Ctot can be described as a function of the unbound concentra-
tion (Eq. 4):
Ctot ¼ Cu  1þ CbmaxCu þ Cu50
 
ð4Þ
where Cbmax is the maximum concentration bound to eryth-
rocytes and Cu50 is the unbound concentration leading to half
maximum binding.With a blood:plasma ratio of approximately
50 [7], Ctot will mainly reflect Cb. By assuming that Cu is small
relative to Cu50 and by standardizing Cbmax to a hematocrit
value of 45 %, Eq. 4 can be written as Eq. 5:
Ctot ≅ Cb ¼ Cstd  R Hct45% ð5Þ
where Cstd is the standardized concentration proportional to
Cu, and R is the ratio between Cbmax and Cu50 at a hematocrit
of 45 %. Equation 5 was included in the model by relating the
pharmacokinetic parameters and predictions to Cstd rather
than to Ctot. Potential concentration-dependent binding of
tacrolimus to erythrocytes was investigated using Eq. 6:




where Cstdmax and Cstd50 are estimable parameters reflecting
maximum binding capacity of tacrolimus to erythrocytes and
the standardized concentration associated with half maximum
binding, respectively. Similar principles to those described for
hematocrit were used to investigate the standardization of
plasma protein binding using serum albumin concentrations.
The pharmacokinetic disposition parameters were related
to fat-free mass using theory-based allometric coefficients of
3/4 for clearances and 1 for volumes of distribution [20]. Fat-
free mass was predicted from total body weight, height and
sex (Eqs. 20 and 21 in [21]). Potential additional effects of fat
mass (i.e. total body weight—fat-free mass) to the effect of
fat-free mass on the pharmacokinetic parameters were esti-
mated as described by Anderson and Holford [20].
All available patient characteristics were evaluated as co-
variates on parameters where an effect was biologically plau-
sible or if an effect was found in previous studies. Regarding
covariates for which little is known about the mechanism of
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influence on tacrolimus pharmacokinetics (age, time after trans-
plantation, liver function test values), continuous covariate
effects were initially investigated by binning observed concen-
trations by covariate value (e.g. age bins of 20–29 years,
30–39 years and so on). The early post-transplant period was
binned by dividing it into 12 time intervals with similar number
of observations in each interval: day 2, 3, 4–5, 6–7, 8–10,
11–14, 15–21, 22–28, 29–42, 43–56, 57–70 and >70 days. A
mean pharmacokinetic parameter (CL or F) was estimated
within each bin relative to a reference bin. Empirical models
(linear, power, exponential or sigmoid functions) were subse-
quently used to match the discrete distribution of parameter
values as a function of the continuous covariate and of time.
This method helps to identify and obtain initial estimates of
continuous functions that describe the data when there is little
prior information on what relationship to expect [22]. Binary
covariate effects (e.g. sex) were investigated by estimating the
fractional change in one group compared to the other.
Model evaluation and statistical analysis
Model selection was guided by biological plausibility and the
likelihood ratio test [difference in objective function value
(ΔOFV)]. A decrease in OFV of >6.6 was considered to be
statistically significant for the addition of one parameter
(p <0.01) [23]. Prediction-corrected visual predictive checks
(pcVPCs) were generated to compare observed data with
90 % prediction intervals constructed from 100 simulated sub-
sets of the original dataset [24]. Time after dose, time after
transplantation and other continuous covariates were used as
independent variables in pcVPCs. Covariates were included
stepwise and subsequently independently deleted from
the full model (backward elimination) to evaluate their
final statistical contribution [25]. Confidence intervals
(CIs) of the parameter estimates were generated from
1,000 nonparametric bootstrap replicates [26]. These
were used to guide model simplification. Random ef-
fects were retained if the lower 2.5th percentile did not
approach zero. Covariates were retained if the 95 % CI
of the covariate coefficient estimate did not include the
value equivalent to no effect. To describe variability in
hematocrit between and within patients, hematocrit was
modeled by BSV and BOV (considering each hematocrit
measurement as a single occasion). The time course of hemat-
ocrit after transplantation was described by a sigmoid Emax
function.
Modeling was performed in NONMEM® v. 7.2 [23] using
the first order conditional estimation method with interaction.
Models and bootstrap replicates were run using Wings for
NONMEM® [27]. Statistical and graphical analyses were
performed using the statistical package R® (v. 2.15.0; R
Foundation for Statistical Computing, Vienna, Austria).
Means for normally distributed covariates were compared
using two-tailed t tests with assumption of equal variance. If
not stated otherwise, descriptive statistics are expressed as the
mean ± standard deviation.
Results
Patients and data
Demographic and clinical characteristics, details about tacro-
limus treatment and the number of missing covariate values
are presented in Table 2. Patients using carbamazepine (n =2)
were excluded because of potential drug interaction with
tacrolimus. Patients using nifedipine (n =26), lansoprazole
(n =12) and/or cinacalcet (n =5) were retained. Figure 1a
shows the evolution of the dose-normalized tacrolimus trough
whole blood concentrations after transplantation. In total,
41 % of the measured trough concentrations in the TDM
group were outside the target concentration ranges defined
by the hospital protocol. The percentage of measured concen-
trations outside these ranges for week 1, 2, 3, 4, 5–6, 7–8 and
9–10 after transplantation were 42, 41, 47, 42, 43, 37 and
36 %, respectively. It was however not known if the clinician
voluntarily had deviated from the protocol.
Hematocrit increased during the first 70 days after trans-
plantation (Fig. 1b). The population baseline hematocrit on
day 1 was estimated to be 29.7 %, increasing towards an
asymptotic value of 37.4 % with half maximum increase on
day 19 post-transplant. BSVand BOVof the hematocrit were
estimated to be 8 and 11 %, respectively. Average hematocrit
did not vary by sex (p =0.28) or CYP3A5 genotype (p =0.51).
Average total body weight was 19 kg higher in males (86±
21 kg) than in females (67±15 kg) (p <0.001). Average fat-
free mass was 18 kg higher in males (64±10 kg) than in
females (46±5 kg) (p <0.001).
Population pharmacokinetic modeling
Structural model
Tacrolimus pharmacokinetics were best described by a two-
compartment model and first order absorption with a lag time.
A study-specific absorption rate and lag time improved the
description of substudy 2.When the BOVwas estimated for F,
the lower 2.5th percentile of the bootstrap distribution of BOV
in the four disposition parameters (CL/F, V1/F, Q/F and V2/F)
approached zero. BOV in these parameters were therefore
removed (ΔOFV+7.3 for four parameters, p =0.12). For the
absorption rate constant (ka), BSV was removed and BOV
was retained (ΔOFV+3.4 by removing BSV, p =0.07;
ΔOFV+28.7 by removing BOV, p <0.001), indicating that
the variability in absorption rate is mainly dependent on
dosing occasion rather than being a subject-specific process.
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We chose to estimate a full correlation matrix between
CL/F, V1/F, Q/F and V2/F (ΔOFV=−59.0 for six parameters,
p <0.001) rather than to estimate BSV in F (ΔOFV=−32.4 for
one parameter, p <0.001). The pcVPC over the range of
hematocrit revealed a systematic prediction error at this stage
(Fig. 2b).
Covariate model
The model fit improved significantly by linearly standardizing
whole blood concentrations to a hematocrit of 45 % (ΔOFV=
−78.3, p <0.001). The estimated value for the parameter R in
Eq. 5 was 0.99, and this parameter was removed without
worsening the model fit (ΔOFV=+1.2, p =0.27). By stan-
dardizing for hematocrit, the systematic prediction error over
the range of hematocrit values was no longer present (Fig. 2c).
Accounting for the possibility of saturated erythrocyte proteins
(Eq. 6) or including similar standardization of the concentra-
tions using serum albumin did not improve the model fit.
The parameters describing the effects of fat mass in addi-
tion to the effect of fat-free mass on the disposition parameters
were estimated to be close to zero [bootstrap means of
0.1 (95 % CI −0.7 to 1.9) for clearances and 0.3 (95 %
CI −0.7 to 2.4) for volumes of distribution]. This indicated
that fat-free mass is a more predictive body size metric for
tacrolimus pharmacokinetics than total body weight. The OFV
did not increase by fixing these parameters to zero. CYP3A5
genotype significantly influenced both CL and F (p <0.001).
After including body size in the model, it was found that F
was significantly lower in females (ΔOFV=−9.8, p =0.002).
When an age-specific value of F was estimated in each of the
five age categories, it became apparent that F changed be-
tween age 40 and 50 years and was essentially constant at a
lower relative value in patients aged <40 years and constant
Table 2 Demographic and clinical data
Data Number Meana 95 %
observation
interval
Change in TDM Group after transplantation Number of
missing data
pointsDay 1 Day 70
Mean 95 % observation
interval




Sex (male /female) 50/19 0/69
CYP3A5 genotype (*1/*1, *1/*3, *3/*3) 0/10/59 0/69
Age (years) 43 22–73 0/69
Height (cm) 176 151–197 0/69
Total body weight (kg) 81 51–131 83 53–140 80 49–128 142/1,546
Predicted fat-free mass (kg) 59 40–82 60 41–84 55 39–82 142/1,546
Hematocrit (%) 36 29–43 31 25–39 38 32–42 109/1,546
Serum creatinine (μmol/L) 147 73–347 409 123–1,079 120 78–208 2/1,546
C-reactive protein (mg/L) 7 <0.6–24 12 <0.6–34 3 <0.6–10 49/1,546
Serum albumin (g/L) 42 33–47 37 27–45 45 37–50 498/1,546
Total serum bilirubin (μmol/L) 7 3–13 5 1–14 6 3–15 500/1,546
Aspartate aminotransferase (IU/L) 23 15–40 35 13–111 20 14–29 498/1,546
Alanine aminotransferase (IU/L) 31 10–91 50 13–170 22 11–43 498/1,546
Alkaline phosphatase (IU/L) 66 30–106 60 34–95 70 41–105 499/1,546
Pharmacokinetic data (TDM Group)
Samples 1,032
Samples per patient 23 13–29
Tacrolimus trough concentration (μg/L) 7.0 2.7–12.4
Pharmacokinetic data (Intensive Group)
Samples 514
Samples per patient 18 9–39
Tacrolimus concentration (μg/L) 11.3 3.4–26.7
CYP3A5, Cytochrome P450 3A5; TDM, therapeutic drug monitoring
a Calculated from mean value across all observation times in each patient
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at a higher relative value in patients aged >55 years. A
sigmoid function of age was useful to describe these changes
and improved the model further (ΔOFV=−18.1 for three
parameters, p <0.001) (Eq. 7):
FGRP ¼ Fminage þ 1−Fminage
1þ AgeFage50
 −Hill Fage ð7Þ
where Fminage is the asymptotic value of F at a low age
relative to the highest value of F with increasing age, and
Fage50 is the age of the half maximum change in F with the
associated shape coefficient HillFage. The estimates of Fage50
and HillFage were similar for males and females, whereas
Fminage was different between males and females. These
results indicate that the sex difference in F is greatest in
younger patients (<40 years) and that the difference dimin-
ishes at age >55 years (Fig. 3a).
The time interval-specific value of F changed systematical-
ly with time after transplantation. These changes could be
described using two distinct sigmoid functions of time after
transplant (Fig. 4a and Eq. 8). A random effect was included
to describe BSV in the extent of change at a late time point:















where Fi is the individual value of F, Fmaxearly is the maxi-
mum value of F immediately after transplantation, Fearly50 is
the day with half maximum early effect on F with the associ-
ated shape coefficient HillFearly describing the steepness of this
change, Flate50 is the day with half maximum later effect on F
with the associated steepness coefficient HillFlate, Fmaxlate is
the asymptotic maximum value of F with increasing post-
transplant time and eηi is the difference between the individual
asymptote and the population asymptote, where ηi’s are
assumed to be normally distributed with mean zero and var-
ianceωFlate
2. The day of transplant was defined as day 1. The
six sigmoid model parameters replaced the 12 time interval
parameters without loss in model goodness of fit (ΔOFV=
−64.8 vs. −69.5, respectively, compared to a model without
time after transplantation as a covariate). Estimation of BSVin
Fmaxlate resulted in a further decrease (ΔOFV=−40.7 for one
parameter, p <0.001). The data did not support estimation of
BSV in any of the remaining parameters in Eq. 8. No time-
varying covariate, including prednisolone dose and liver func-
tion test values, replaced the empirical time model for F
without a loss in model goodness of fit.
Model reduction and evaluation
The study-specific residual errors for substudies 1 and 4 were
similar and joined (ΔOFV+0.9 for one parameter, p =0.34).
The lower 2.5th percentile of the bootstrap distribution of the
additive residual error term and BSV in the residual error
approached zero. Therefore, only the proportional error term
was retained. All random effects describing correlations
between disposition parameters except from between CL/F
and Q/F were removed because their 95 % CIs included zero.
The effect of CYP3A5 genotype on CL was removed because
the 95 % CI of 0.81–1.46 did not support its inclusion in
addition to an effect on F, which had a 95%CI not including 1
(0.39–0.83) (ΔOFV +0.01 for one parameter, p =0.91).
Removing the remaining covariates significantly worsened
the goodness of fit.
Expressed as bootstrap averages of the final model (Table 3),
we found that F was 49% lower in CYP3A5 expressers than in
Fig. 1 a Dose-normalized whole blood trough concentrations of tacro-
limus (tac) observed in the TDM Group during the first 70 days after
transplantation. Thin lines 44 individual patients, thick line a smoother to
show the trend with time. b Time course of hematocrit (%) during the first
70 days after transplantation. Thin lines 44 individual patients that were
followed during this period, thick line sigmoid Emax model fit to the data
to describe changes in hematocrit as a function of time
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Fig. 3 a Thick horizontal lines Age interval-specific average values of
bioavailability (F) estimated in males (black) and females (gray) relative to
males aged >60 years (defined asF=1). Lines Model-estimated functions for
changes in bioavailabilitywith age inmales (black dashed) and females (gray
solid). b pcVPC using the final model as a function of age. Solid red line
Median observed tacrolimus concentration (prediction-corrected), dashed red
lines 90 % observation interval (5th to 95th percentile), solid black line
median model-predicted concentrations, dashed black lines 90 % prediction
interval. Gray-shaded areas 95 % CI for each model-predicted percentile
Fig. 2 a Prediction-corrected tacrolimus whole blood concentrations
over the range of hematocrit, b prediction-corrected visual predictive
check (pcVPC) over the range of hematocrit using the basemodel without
covariates, c pcVPC over the range of hematocrit using the base model
with hematocrit standardized concentrations. Solid red line Median
observed tacrolimus concentration (prediction-corrected), dashed red
lines 90 % observation interval (5th to 95th percentile), solid black line
median model-predicted concentrations, dashed black lines 90 % predic-
tion interval.Gray-shaded areas 95% confidence intervals (CIs) for each
model-predicted percentile
Fig. 4 a Thick horizontal lines Time interval-specific average values of
bioavailability after transplantation, estimated relative to the value at day 5
(defined asF=1).Thin continuous lineModel-estimated time course of relative
bioavailability during the first 70 days after transplantation. b pcVPC using the
final model as a function of the first 70 days after transplantation. Solid red line
Median observed tacrolimus concentration (prediction-corrected), dashed red
lines 90%observation interval (5th to 95th percentile), solid black line median
model predicted concentrations, dashed black lines 90 % prediction interval.
Gray-shaded areas 95 % CI for each model-predicted percentile
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Table 3 Original data estimates and bootstrap average parameter estimates with 95 % confidence intervals
Parameter Unit Original data estimatea Bootstrap average Bootstrap 95 % CIb
CL/Fn L/h 20.5 20.5 17.3–24.6
V1/Fn L 105 107 87–136
Q/Fn L/h 35.8 37.3 21.5–48.5
V2/Fn L 450 424 297–583
ka h
−1 1.14 1.18 0.80–1.78
ka, study 2 h
−1 0.37 0.38 0.31–0.48
Lag time h 0.21 0.22 0.20–0.24
Lag timestudy 2 h 0.82 0.81 0.65–0.90
Covariates on F
CYP3A5 *1/*3 factor 0.51 0.51 0.42–0.62
Age and sex
Fminage, females 0.44 0.43 0.23–0.60
Fminage, males 0.68 0.66 0.36–0.89
Fage50 years 44 47 39–70
HillFage 12.2 14.0 3.5–24.9
Time, early
Fmaxearly 1.87 2.04 1.60–3.9




Fmaxlate 0.27 0.28 0.14–0.49
Flate50 days 30 31 24–40
HillFlate 2.3 2.5 1.6–4.7
BSV
CL/Fn % 33 31 21–40
V1/Fn % 14 14 0.2–37
Q/Fn % 91 86 51–114
V2/Fn % 52 52 32–74
HillFlate % 117 113 78–146
Correlation
CL/Fn∼Q/Fn 0.75 0.74 0.41–0.92
BOV
Fn % 16 16 13–18
ka % 63 60 41–84
Residual variability
Proportional error % 16.7 16.7 15.2–18.4
Study 2 factor 0.57 0.56 0.41–0.72
Study 3 factor 0.73 0.72 0.57–0.90
CI, Confidence interval, Fn, bioavailability at baseline nadir (5 days after transplantation); CL/Fn, apparent clearance; V1/Fn, apparent central volume of
distribution; Q/Fn, apparent intercompartmental clearance; V2/Fn, apparent peripheral volume of distribution; ka, absorption rate constant; FFM, fat-free mass;
Fminage, the minimum value of F at decreasing age relative to reference (male > 60 years); Fage50, the age with half maximum effect on F; HillFage, shape
coefficient for the change in Fwith age; Fmaxearly, themaximum increase in F immediately after transplantation relative to Fn; Fearly50, the daywith half maximum
early effect on F;HillFearly, shape coefficient for the change in F at early time; Fmaxlate, maximum increase in F at later time point, relative to Fn; Flate50, the daywith
half maximum later effect on F; HillFlate, shape coefficient for the change in F at later time; BSV, between subject variability; BOV, between occasion variability
The final model was parameterized as follows: CL/Fn=20.5×(FFM /60)3/4 L/h; V1/Fn=107×(FFM /60) L; Q/Fn=37.3×(FFM /60)
3/4 L/h; V2/Fn=424×(FFM /60) L
F=[2.04+(1−2.04)/(1+(TXT/2.5)−9.4 )]×[1+0.28 / (1+(TXT/31)−2.5 )]×[Fminage+(1−Fminage)/(1+(AGE/47)−14 )]× FCYP where Fminage=0.43 in
females and 0.66 in males, FCYP is 0.51 in CYP3A5 expressers and 1 in CYP3A5 nonexpressers and TXT is the time after transplantation in days
a Standardized to 40-year-old male, CYP3A5 nonexpresser with fat-free mass of 60 kg and hematocrit of 45 %, at a time point with the lowest estimated
bioavailability (Fn, day 5 post-transplant)
b 2.5–97.5 percentile obtained from 500 bootstrap replicates
c Upper bound
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CYP3A5 nonexpressers. Furthermore, F was reduced to 0.43
and 0.66 for females and males, respectively, at the lowest ages
compared to the plateau value set to 1 at highest age in males.
The plateau value for females with increasing age was estimat-
ed as 1 (not different from males). The steepest change in F with
age occurred around the age of 47 years for both sexes. More-
over, F was 104 % higher immediately after transplantation
relative to its lowest value, followed by a steep decrease
(HillFearly=9.4) to a nadir (the reference baseline where F is
defined as 1), with half of the change at day 2.5 after transplan-
tation. F then increased more slowly (HillFlate=2.5) to an asymp-
totic value 28% higher than the nadir (BSV=113%)with half of
the change after 31 days. PcVPCs indicated that the model was
able to predict tacrolimus concentrations over the range of all the
included covariates (shown for age in Fig. 3b and for time after
transplantation in Fig. 4b).
Discussion
In this study, a population pharmacokinetic model was devel-
oped for tacrolimus by combining trough concentration data
from the early post-transplant phase with rich sampling from
patients in a stable phase after kidney transplantation. Hemat-
ocrit influenced the whole blood concentrations, while fat-free
mass, CYP3A5 genotype, sex, age and time post-transplant
were identified as factors influencing tacrolimus individual
dose requirement to achieve a target concentration proportion-
al to the unbound active drug. Although the importance of
hematocrit has been highlighted in several population phar-
macokinetic analyses of tacrolimus in kidney transplant pa-
tients [28–32], these analyses used hematocrit as an empirical
predictor only of clearance or volume of distribution, but not
both simultaneously. A novel approach of our study was the
modeling of hematocrit as a covariate to adjust measured whole
blood concentrations based on the theory that all whole blood-
based pharmacokinetic disposition parameters are equally
influenced by hematocrit for a low extraction ratio drug such
as tacrolimus. When not accounting for differences in hemato-
crit, the pharmacokinetic model showed a clear systematic
prediction error across the range of observed hematocrit values.
The systematic prediction error was, however, no longer pres-
ent after correction for the predictions to account for the actual
hematocrit value (Fig. 2). This can be understood in terms of
pharmacokinetic theory for a low-extraction-ratio drug, with
elimination and distribution processes being independent of
unbound drug concentration. Of note, the same theory de-
scribed for hematocrit also applies to the binding of tacrolimus
to albumin, α1-glycoprotein and lipoproteins in plasma [8, 9].
Although we did not identify any influence of albumin, it might
have been obscured by the correlation between increases in
albumin and hematocrit following kidney transplantation.
The challenge of reaching and maintaining a target con-
centration of tacrolimus during the first months after kidney
transplantation has been described previously by Ekberg et al.
who observed that approximately 50 % of tacrolimus trough
concentrations during the first 8 post-transplant weeks were
outside the intended range (3–7 μg/L) [6]. In our study, the
percentage outside the target range was somewhat lower, but it
was not reduced during the first 6 weeks after transplantation
(42 % week 1, 43 % week 5–6). These challenges are, at least
in part, related to the substantial increase in hematocrit fol-
lowing kidney transplantation (Fig. 1b) and high hematocrit
within-subject variability (CV 11 %). Based on pharmacolog-
ical theory and confirmation that hematocrit standardization is
consistent with unbound concentration-independent pharma-
cokinetics, we recommend that tacrolimus whole blood con-
centrations be standardized to a hematocrit (Hct) of 45 %
(Cstd=Ctot×45 %/Hct) to reflect the unbound (active) drug
more closely. This recommendation is based on the same
well-known concepts that have guided the interpretation of
phenytoin plasma concentration measurements when plasma
proteins differ from normal [33, 34].
There is no consistent appreciation of the role of body size
as a determinant of tacrolimus distribution and elimination
[35], despite its biological basis and clinical use for predicting
initial doses. This may be partly explained by small ranges of
size, but also by not recognizing the role of body composition
(fat-free mass and fat mass) as a determinant of functional
body size. We investigated a large range of weights and
identified fat-free mass as a predictor of tacrolimus pharma-
cokinetics, which to our knowledge is a novel finding. It is
reasonable to accept fat-free mass as a predictor of tacrolimus
clearance because fat mass is not expected to influence met-
abolic capacity directly [20]. The fact that volume of distribu-
tion of tacrolimus appeared to be closer related to fat-free mass
than to total body weight indicates that the extent of tissue
distribution of tacrolimus may be determined mainly by bind-
ing to proteins in lean tissues. For the patients in the current
dataset with the lowest and highest total body weights (males
of 43 kg and 160 kg with predicted fat-free masses of 39 and
95 kg, respectively), the model predicts apparent clearances of
16 and 27 L/h, respectively (given otherwise equal conditions;
see Table 3). These calculations show that although total body
weight may differ by fourfold in this patient group, the
required dose differs by less than twofold and that the currently
applied initial dose algorithm increases risk of overtreatment in
obese patients. Indeed, previous studies have reported that high
tacrolimus concentrations were more frequently observed in
patients with higher weights [36, 37]. The proposed model
provides a more rational use of body size for tacrolimus dose
selection.
After appropriately accounting for body size differences in
the model, we then identified sex differences in the pharma-
cokinetics of tacrolimus. The model fit was slightly better
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using sex as a covariate on bioavailability rather than on
clearance, and there was little evidence for an additional effect
on clearance. This result is somewhat supported by previously
reported results [37, 38], although most population studies on
tacrolimus did not establish a relationship with sex [29, 35,
39]. The difference between males and females was most
apparent in younger patients, and as age increased, bioavail-
ability increased for both sexes while the sex difference
diminished. It has been previously described that sex
differences in the pharmacokinetics of CYP3A substrates
seem to be more pronounced at younger ages compared
with in the elderly [40]. The effect may alternatively be
caused by sex- and/or age-related differences in intestinal
P-glycoprotein (ABCB1) activity. Previous reports have
also described higher tacrolimus concentrations in elderly
patients [37, 41, 42], which is consistent with our find-
ings. It should be noted that only four females in our
study were aged >50 years. Further studies are needed to
recommend appropriate initial dosing of tacrolimus based
on sex and age.
A major limitation of our study was the use of a high
proportion (67 %) of trough concentrations. Concentrations
measured at trough provide only modest pharmacokinetic
information. Another limitation was that seven patients who
received simultaneous pancreas–kidney transplantation and
two patients who used carbamazepine were excluded from
the analysis. This may have led to underprediction of the
variability seen across patients in a true clinical setting. Fur-
thermore, conversion between multiple analytical assay tech-
niques for tacrolimus measurements may have introduced
additional overall variability to the analysis. Hematocrit-
related bias in concentration determinations by analytical im-
munoassays should however not be a relevant limitation be-
cause CMIA is not known to be affected by hematocrit [1]. All
samples analyzed with MEIA had corresponding hematocrit
values not associated with bias (25–45 %) [43]. Finally, the
95 % interval of the ordered observed hematocrit values was
29–43 %. In general, extrapolation of results to patients with
covariate values outside of the investigated range should be
done with caution. Yet, because the hematocrit model has a
mechanistic basis, extrapolation is more likely to be reliable.
The whole blood concentration–effect relationship of ta-
crolimus is poorly characterized, and there is no consensus
among transplant centers on an optimal tacrolimus concentra-
tion [1, 2]. Although a trough concentration range of 3–7 μg/L
has been proposed [44] and is used at our center, ranges of
5–10 or 10–15 μg/L are targeted at other centers [45]. An
increasing hematocrit leads to a decrease in therapeutically
active unbound concentrations with time after transplantation if
doses are adjusted to maintain unchanged total whole blood
concentrations [9]. Differences in active unbound concentra-
tions not reflected by whole blood concentrations will be a
confounding factor in studies attempting to characterize the
whole blood concentration-effect relationship. In a study in
liver transplant patients, the estimated unbound concentrations
of tacrolimus were significantly lower in patients experiencing
acute rejection than in stable patients (p <0.001), without a
difference in whole blood concentrations (p =0.5) [8]. Stan-
dardizing whole blood concentrations to hematocrit in future
studies should improve our understanding of the concentra-
tion–effect relationship for tacrolimus and allow a more con-
sistent target concentration to be achieved.
In conclusion, a population pharmacokinetic model was
developed for tacrolimus in kidney transplant patients. Fat-
free mass, CYP3A5 genotype, sex, age and time post-
transplant were identified as predictors of individual tacroli-
mus dose requirement. Allometric scaling to fat-free mass
provides a more rational use of body size than linear scaling
to total body weight. Hematocrit is a predictor of variability in
tacrolimus whole blood concentrations, but it is not expected
to influence unbound (therapeutically active) concentrations.
Because hematocrit is highly variable in kidney transplant
patients and increases substantially after kidney transplanta-
tion, hematocrit is a key factor for interpretation of tacrolimus
whole blood concentrations.
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